Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cara Haymaker

Showing results (41-50 of 108) with videos related to

Pageof 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2021
Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid TumorsApostolia M Tsimberidou, Philip A Beer, Carrie A Cartwright, et al.
Arxiv|December 25, 2025
From Classical Machine Learning to Emerging Foundation Models: Review on Multimodal Data Integration for Cancer ResearchAmgad Muneer, Muhammad Waqas, Maliazurina B Saad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2026
NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal CanalVan K Morris, Kristen K Ciombor, Lianchun Xiao, et al.
Cancer Immunology Research|July 29, 2015
Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case ReportIsabella C Glitza, Cara Haymaker, Chantale Bernatchez, et al.
JCO Global Oncology|December 23, 2025
Linking Microbiome Diversity and Immune Profiles in Ethiopian Patients With Cervical CancerKyoko Yoshida-Court, Brhanu Teka, Tatiana Cisneros Napravnik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2022
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)Hani Babiker, Erkut Borazanci, Vivek Subbiah, et al.
JAMA Oncology|September 30, 2018
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical TrialErminia Massarelli, William William, Faye Johnson, et al.
Journal for Immunotherapy of Cancer|June 7, 2018
Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approachesEdwin R Parra, Pamela Villalobos, Carmen Behrens, et al.
Oncoimmunology|August 15, 2025
Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanomaMerve Hasanov, Simin Kiany, Marie-Andrée Forget, et al.
European Urology|April 28, 2026
Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 TrialsAlexander D Sherry, Van To, Criselle D'souza, et al.
Pageof 11

Showing results (41-50 of 108) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2021
Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid TumorsApostolia M Tsimberidou, Philip A Beer, Carrie A Cartwright, et al.
Arxiv|December 25, 2025
From Classical Machine Learning to Emerging Foundation Models: Review on Multimodal Data Integration for Cancer ResearchAmgad Muneer, Muhammad Waqas, Maliazurina B Saad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2026
NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal CanalVan K Morris, Kristen K Ciombor, Lianchun Xiao, et al.
Cancer Immunology Research|July 29, 2015
Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case ReportIsabella C Glitza, Cara Haymaker, Chantale Bernatchez, et al.
JCO Global Oncology|December 23, 2025
Linking Microbiome Diversity and Immune Profiles in Ethiopian Patients With Cervical CancerKyoko Yoshida-Court, Brhanu Teka, Tatiana Cisneros Napravnik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2022
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)Hani Babiker, Erkut Borazanci, Vivek Subbiah, et al.
JAMA Oncology|September 30, 2018
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical TrialErminia Massarelli, William William, Faye Johnson, et al.
Journal for Immunotherapy of Cancer|June 7, 2018
Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approachesEdwin R Parra, Pamela Villalobos, Carmen Behrens, et al.
Oncoimmunology|August 15, 2025
Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanomaMerve Hasanov, Simin Kiany, Marie-Andrée Forget, et al.
European Urology|April 28, 2026
Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 TrialsAlexander D Sherry, Van To, Criselle D'souza, et al.
Pageof 11